key: cord-0998648-imnh2iu4
authors: Jaimes-Albornoz, Walter; Ruiz de Pellon-Santamaria, Angel; Nizama-Vía, Ayar; Isetta, Marco; Albajar, Ines; Serra-Mestres, Jordi
title: Catatonia in older adults: A systematic review
date: 2022-02-19
journal: World J Psychiatry
DOI: 10.5498/wjp.v12.i2.348
sha: aba59159223be4d15b5adc02516e2dba46b9385e
doc_id: 998648
cord_uid: imnh2iu4

BACKGROUND: Catatonia is a complex psychomotor syndrome that often goes unrecognized and untreated, even though its classification has evolved in recent years. Prompt and correct identification of catatonia allows for highly effective treatment and prevention of possible complications. The underrecognition of catatonia in older patients is also frequent, and research in this population is scarce. AIM: To conduct a systematic review of the literature on catatonia in older people to ascertain its clinical characteristics across settings. METHODS: Following the PRISMA guidelines, MEDLINE, EMBASE, and PsycINFO databases were searched from inception to December 2021, with a strategy aimed at identifying all articles published on catatonia in older adults. Titles and abstracts were scanned and selected independently by two authors. Papers investigating issues related to catatonia and/or catatonic symptoms in older people, with English abstracts available, were included. References of selected articles were revised to identify other relevant studies. RESULTS: In total, 1355 articles were retrieved. After removing duplicates, 879 remained. Of the 879 identified abstracts, 669 were excluded because they did not meet the inclusion criteria. A total of 210 articles underwent full text review, and 51 were eliminated for various reasons. Fourteen more articles were selected from the references. Overall, 173 articles were reviewed: 108 case reports, 35 case series, 11 prospective cohort studies, 6 case-control studies, 3 retrospective cohort studies and 10 reviews. We found several particular aspects of catatonia in this population. Catatonia in older patients is highly prevalent and tends to have a multifactorial etiology. Older patients, compared to younger patients, have a higher risk of developing catatonia with benzodiazepine (BZD) withdrawal, in bipolar disorder, and in the general hospital. Age, together with other risk factors, was significantly associated with the incidence of deep venous thrombosis, neuroleptic malignant syndrome poor outcome, other complications and mortality. Treatment with BZDs and electroconvulsive therapy is safe and effective. Prompt treatment of its cause is essential to ensure a good prognosis. CONCLUSION: Catatonia in older patients is highly prevalent and tends to have a multifactorial etiology. The risk of developing catatonia in some settings and conditions, as well as of developing complications, is high in this population. Symptomatic treatment is safe and effective, and timely etiologic treatment is fundamental.

Catatonia is a psychomotor syndrome caused by physical illnesses, such as infections; endocrine, metabolic, and neurologic disorders; psychiatric conditions, mainly affective and psychotic; and medications and other substances [1] . The contemporary concept of catatonia has evolved significantly. The Diagnostic and Statistical Manual -Fifth Edition (DSM-5) classifies catatonia either as a specifier of all mental disorders, as secondary to a general medical condition (GMC), and as catatonia not otherwise specified for when the syndrome is identified but not yet their etiology [2] . Based on a review of the available evidence published in recent decades and considering their clinical utility and global applicability, the International Classification of Diseases -11 th Edition classifies catatonia as a new diagnostic group at the same hierarchical level as the other included disorders. This edition, approved in May 2019, considers that catatonia can be caused by mental disorders, psychoactive substances (including medications), and medical conditions. In the former, catatonia is valued with the symptom specifier within the category "psychomotor symptoms" and, in the other two cases, as a secondary presentation form [3] . In patients older than 18 years, catatonia is mostly associated with affective disorders [1] . Its early recognition is important, as it is a potentially deadly syndrome. However, it is highly treatable, usually responding to treatment of the cause and to short courses of benzodiazepines (BZDs) or electroconvulsive therapy (ECT) [4] [5] [6] [7] .

Catatonia is also underrecognized in older adults, something that in this population may lead to delayed treatment, misdiagnosis, adverse events, and even death [8, 9] . Despite the increasing amount of research on catatonia, there have been few specific studies on older patients. This review aims to summarize the published literature on catatonia in older adults to provide up-to-date knowledge about this entity for clinicians working with this population.

This systematic review was conducted using the PRISMA method [10] . The MEDLINE, EMBASE, and PsycINFO databases were searched from inception through December 2021. The search strategy was as follows: CATATONIA/or catatoni*.af. and aged/or "aged, 80 and over"/or frail elderly/or (elder* or "old people" or geriatr* or senior* or aged or "over 65" or "over 80" or "65 year*" or "85 year*").ti,ab. Articles identified were imported into a standard reference manager, EndNote X7, and duplicate manuscripts were removed. Papers that investigated issues related to catatonia and/or catatonic symptoms in older people, with an English abstract available, were included. Titles and abstracts were scanned for relevance. Papers were selected according to the inclusion criteria by two authors independently (Jaimes-Albornoz W and Serra-Mestres J). Full texts were ordered in case of uncertainty to maximize sensitivity. References of selected articles were cross-checked to identify other potentially eligible studies. Case reports, case series, controlled studies, or review articles were eligible for inclusion in this review. The full texts of studies that passed the initial screening were reviewed and potentially excluded based on the same criteria. From this selection we only included Abstracts/Conference proceedings and letters to the editor that describe cases of catatonia whose clinical correlates have not been previously described. The literature search strategy is summarized in the flow chart presented in Figure 1 . We also present all the clinical correlates of our catatonic patients in a psychogeriatric unit (Tables 1, 2 and 3). Information on patients diagnosed with dementia in this series has been published previously [11] .

In total, 173 articles were considered: 108 case reports, 35 case series (12 also carried out a systematic review of the literature), 11 prospective cohort studies, 6 case control studies, 3 retrospective cohort studies, and 10 reviews. All articles were reviewed and are summarized below.

The prevalence of catatonia is largely dependent on its recognition, diagnostic criteria used, and setting. Although the general prevalence of catatonia is not fully known, it is considered to be between 5% and 20% among acute psychiatric patients; however, it varies according to the underlying or comorbid conditions [12] . A prevalence of 14%-71% has been described in mood disorders, 4%-67% in schizophrenia spectrum disorders, and between 4%-46% in GMCs [13] . A recent meta-analysis including 74 studies and 107304 individuals showed an overall pooled mean prevalence of catatonia of 9.2% among subjects diagnosed with a variety of psychiatric and medical conditions [13] .

In the older population, the prevalence of catatonia also seems to vary depending on the setting and diagnostic criteria used. In liaison psychiatry services using the Bush Francis Catatonia Rating Scale (BFCRS) criteria, the prevalence of catatonia was 5.5%[14] and 8.9% [8] . Another study conducted in older patients in an acute inpatient general psychiatry ward reported a prevalence of 11.2% using the BFCRS and 6.1% using the DSM-5 criteria [15] . The prevalence was noted to be higher in acute psychogeriatric units in the United Kingdom (Table 1) and Spain[16] , where the prevalence was 27% and 39.6% and 24.3% and 20.8%, respectively, using the BFCRS and DSM-5 criteria.

The specific brain mechanisms underlying catatonia are still poorly understood. The model developed by Northoff et al [17, 18] , who hypothesized that catatonic symptoms are mainly associated with orbitofrontal-prefrontal/parietal cortical dysfunction ('top-down' model of catatonia), abnormal 'horizontal' cortical-cortical modulation, and basal ganglia-cortical dysfunction (a 'bottom-up' mechanism), is criticized because the results are inconsistent and have generally been limited to schizophrenic patients with catatonia [19] . Studies with structural and functional brain imaging [20] , clinical observations made after lobotomies and frontal lobe lesions, and experiments carried out in animals[21] have described incompatible results with Northoff's theory[17,18]'s theory. We are still far from having an integrative pathophysiological model of catatonia resulting from clinical, structural, and functional abnormalities of such a different nature. In this regard, only two articles were found about older people with catatonia that used brain imaging. The first was in patients with bipolar disorder (BD) and major depressive disorder (MDD), employing functional near-infrared spectroscopy [22] , and the other used SPECT in The etiology was multifactorial in 50% of the cases. 6 patients had dementia. In 3 of them catatonia was associated with the use of neuroleptics, in 1 with neuroleptics and a urinary infection (she also had delirium), in another with major depression and in only one dementia was a possible etiology. 40% of the cases developed catatonia secondary to affective disorders and 10% to schizophrenia spectrum disorder. In the total sample there were 14 patients with dementia. The catatonia rate in these patients was 42.8% (6 of 14). 9 patients received treatment for catatonia with lorazepam, all of which achieved complete remission, 1 of the these was also treated with clonazepam. 1 patient was treated with sodium valproate and achieved a partial response. 3 patients developed complications secondary to catatonia. One had an elevated creatine kinase of 1083 IU/L, another a deep venous thrombosis, and the last one, hypokalemia

Conclusions Catatonia is a very prevalent entity in the psychogeriatric ward. The etiology is usually multifactorial. This condition occurred frequently in patients admitted with dementia. Treatment with lorazepam is highly effective and safe DSM-5: Diagnostic and Statistical Manual -Fifth Edition. It has also been suggested that catatonia could be a manifestation of intense anxiety and/or fear, resembling tonic immobility in animals, an evolutionary adaptive defense strategy to survive contact with predators attacking moving prey [24] . In humans, fear could also be caused by internal events and psychopathological experiences, such as hallucinations and delusions or anxiety/fear. This freezing would correspond to the immobility, stupor, catalepsy, and mutism observed in catatonia. Alternatively, catatonic excitement would be analogous to the 'fight-flight' response mediated by the 

The clinical presentation of catatonia in older adults (frequency of catatonic signs and clinical types) is generally similar to that of younger patients. Table 3 shows the frequency of signs of catatonia evaluated with the BFCRS in the 5 prospective observational studies carried out in older people [8, 11, [14] [15] [16] . Two clinical types of catatonia have been consistently reported in both populations[1,28]. A hypokinetic variant (retarded-stuporous) is characterized by reduced movement or immobility, mutism, and withdrawal. This is most frequently observed in depressive disorders and GMCs. A hyperkinetic or excited variant, presenting with increased aimless motor activity (qualitatively different from the overactivity of pure mania, which is purposeful), confusion, and frequent autonomic dysfunction, is mostly observed during manic episodes and in delirious mania. It is noteworthy that both forms of catatonia can coexist in the same patient, occurring in quick succession[1]. A forgotten subtype of catatonia, also described in older people [29] , is periodic catatonia. It is characterized by rapid onset, brief and recurrent episodes of catatonia with a longitudinal course. Prognosis is typically better than systematic catatonia, which is insidious and progressive. If it is properly identified can respond extremely well to ECT [29] .

The assessment of catatonia requires careful observation during the clinical interview and the elicitation of specific signs during the neurological examination [28] . The routine use of validated rating scales is recommended to facilitate the identification of catatonic signs and the diagnosis of catatonia [30] . In adult patients, seven catatonia rating scales are available. The BFCRS is the most commonly used in research and clinical settings, including older people, because of its validity and reliability and its ease of administration [28, 30] . It is also very sensitive, requiring only 2 out of 14 signs of the screening instrument to diagnose this condition [30] . The DMS-5 states that a diagnosis of catatonia can be made if there are at least three symptoms out of 12 presents at the time of assessment: Stupor, catalepsy, waxy flexibility, mutism, negativism, posturing, mannerisms, stereotypy, agitation, grimacing, echolalia and echopraxia [2] .

The association of catatonia and delirium has been increasingly described [31, 32] . Delirium is considered the most salient factor to predict a medical cause of catatonia [ of cases of older adults with catatonia in acute medical settings, in which the clinical presentation was generally in the retarded-stuporous form. This high prevalence decreases significantly in acute psychogeriatric wards, where delirium was described in 4.8%[16] and 10%[11] of catatonic cases. The differential diagnosis between catatonia and delirium is challenging, as both cause prominent psychomotor abnormalities. Delirium's classification predominantly relates to its motor aspects and is thus divided into hyperactive, hypoactive, and mixed forms [31] . There are also hypoactive and hyperactive forms of catatonia. Catatonia can be misdiagnosed as delirium and managed as such, and while delirium appears in the list of differential diagnoses of catatonia, the latter rarely figures into that of delirium[32]. Furthermore, unlike delirium, approximately 80% of catatonia cases of medical etiology are due to neurological disorders [33] . However, there are differences in their pharmacological management. The treatment of choice in catatonia, lorazepam, is rarely the treatment of choice in delirium, except when caused by BZD withdrawal. The most widely used symptomatic treatment of choice in delirium, antipsychotics, is generally to be avoided in the management of catatonia. Therefore, the ability of clinicians to ascertain a catatonic dimension in cases of delirium will facilitate selection of the appropriate treatment[31,32]. February 19, 2022

Volume 12 Issue 2

Catatonia in older people often presents acutely, but it can also have an insidious presentation. The duration can be transient or chronic, lasting for weeks, months or even years [37, 38] . The total duration of illness could be significantly lower if the etiology is a GMC when compared with affective or psychotic disorders [38, 39] . Acute catatonia has a good prognosis if it is diagnosed early, its symptoms and etiology are treated in a timely fashion, and the necessary measures are taken to prevent complications. If complications are already present, they are treated aggressively [28] . In organic catatonia, structural brain lesions may have a worse prognosis than metabolic causes [8, 40] . Older patients in general hospitals with a longer duration of untreated catatonia may have a worse outcome in terms of rates of complications (40%) and even death (20%) [8] .

Catatonia may develop a chronic or continuous course in some patients, mainly with chronic psychoses. In a study in chronically hospitalized older schizophrenic patients, catatonic symptoms were less common and less severe than in acute hospital patients, but the clinical pattern was similar [37] . According to the authors of the study, these findings suggest that catatonic phenomena may persist for years, a course described by Kahlbaum in several cases where catatonia persisted, in some patients, until their death[37]. Most case reports of catatonia in affective disorders have been published emphasizing the unusualness of the presentation (patient that can masquerade as Creutzfeld-Jakob disease [136] ), the associated psychopathology (cases with nihilistic delusions suggestive of Cotard's syndrome [137, 138] ), or the comorbid conditions present (the affective cases described in the sections on catatonia secondary to GMCs or drug use/withdrawal).

Reports of older patients with catatonia in psychotic disorders are sporadic. Cases of catatonia have been described in association with schizophrenia [139] , psychotic disorder not otherwise specified[16], brief psychotic disorder [135] and schizoaffective disorder [11, 15, 16] . In a study conducted in older adults with schizophrenia, a catatonia prevalence of 69% using BFCRS criteria was found [37] . In acute inpatient wards, schizophrenia spectrum disorders (SSD) is the third most frequent condition in catatonic older patients following affective disorders and those secondary to GMCs[11,16].

Other disorders: Catatonia has been reported in adjustment disorder [16, 140] , substance use disorder [16], conversion disorder [140, 141] , and posttraumatic stress disorder [142] . In one case report, there was a background of melancholia and a recent withdrawal of thioridazine; in another case report, the February 19, 2022

Volume 12 Issue 2 adjustment disorder was diagnosed with depressed mood. In the remaining reports, psychiatric or organic comorbidities were not detailed. Table 4 shows all the etiologies associated with catatonia described above. Better response rates to treatment were found in catatonia related to mood disorders than in catatonia related to nonaffective psychosis[5,6,68]. Even so, ECT is one of the best treatments for catatonic schizophrenia, and this was also described in older patients by Suzuki et al [139] , with excellent response rates in this group. Among the older catatonic patients successfully treated with ECT, the etiology in most of them were mood disorders, followed by those secondary to non-affective psychosis. Less frequently the etiology was related to a GMC.

The number of sessions ranged from 2 to 25, but only 3 patients needed more than 15 sessions to respond. The mean number of sessions among all catatonic episodes was 10.33 sessions/episode. Exceptionally high initial seizure threshold in catatonic older patients treated with ECT has been reported [151] .

The most common application frequencies during acute course ECT were 2 or 3 times a week. Most cases were treated with bifrontotemporal electrode placement and also, there has been reports of patients that received right unilateral ECT with a resolution of catatonia [152, 153] . Furthermore, there is a report of a patient with catatonic schizophrenia who was treated by successful seizure induction by means of ECT, with electrodes applied bilaterally to the parietotemporal region after bifrontotemporal ECT failed to induce adequate seizures [154] . On the other hand, 3 articles described only a partial response to ECT in 3 older patients during a catatonic state after receiving 7-8 ECT sessions [8, 78, 155] . All these cases were associated with GMCs (cognitive impairment, Parkinson's disease, and manganese poisoning).

Two cases of catatonia refractory to ECT treatment have been reported. One on them was associated with encephalitis secondary to ovarian teratoma[58] and another one in a patient with depression and autistic spectrum disorder [151] . Continuation or maintenance ECT is recommended when relapse occurs despite pharmacological treatment and in patients with recurrence of catatonic symptoms when ECT is suspended [139] . Three cases were described with periodic relapses, but each new catatonic episode responded again to a course of ECT. Although there are no absolute contraindications for the use of ECT in older patients and it is considered a safe and well-tolerated treatment, medical risks must be evaluated individually [143, 150] . There are case reports of catatonic patients with unstable or potentially unstable clinical conditions, such as a 95-year-old pacemaker user [156] , full anticoagulation after pulmonary embolism [157] , a 100-year-old patient with severe aortic stenosis [158] , deep venous thrombosis [159] ; that illustrates how, with the proper precautions, the benefits of ECT in such conditions might outweigh its risks.

ECT requires general anesthesia. Serious adverse effects related to ECT are extremely infrequent but include arrhythmia, seizures, or even death, although these have not been specifically reported in this population. Other mild adverse effects are considered transient, but they can be relevant in the older population, such as cognitive impairment, delirium, hypertension, increased risk of falls, or hypomania [150] . Cognitive impairment related to ECT is reported as transient, even in older patients, but limited cases of prolonged amnesia have also been described [160] . [167] . Dopaminergic drugs have also been postulated as potential treatments for catatonia due to the hypothesis that the dopaminergic system is involved in its pathophysiology. There are isolated reports of treatment with bromocriptine[112] and dopamine, the latter being used to treat hypotension during a catatonic state with full recovery [168] . The patient received bupropion as continuation treatment without relapse of catatonia. Also, there have been published a NMS cases which were treated satisfactorily with 25 ECT sessions and bupropion 300 mg/d[164] and with 11 ECT sessions and bromocriptine 15 mg/d [112] . Another article reported a case of successful treatment with methylphenidate in an older depressed patient with catatonic stupor who did not respond to lorazepam [169] . There are articles reporting anecdotal evidence of successful treatment of catatonia with propofol [170] , biperiden [171, 172] , olanzapine [162, 173] and lithium [174] . Another article reported the on efficacy of tramadol in several consecutive catatonic episodes in an older patient with a diagnosis of schizoaffective disorder [132] . Finally, neuromodulation treatments, such as repetitive transcranial magnetic stimulation [111] and transcranial direct current stimulation [175] , were also described as effective. The catatonia treatments used in older people are summarized in Table 5 .

Catatonic states can induce complications in relation to immobility, dehydration or inability to have oral intake, which are especially relevant in older patients. Some of these complications include deep vein thrombosis (DVT), pulmonary embolism, pressure ulcers, infections, acute renal injury, rhabdomyolysis, electrolyte distur-bances, pulmonary aspiration and secondary pneumonitis and/or pneumonia, or muscular contractures [143, 165, 176] . In a retrospective chart review, Ishida et al [176] concluded that age and the presence of risk factors for dynamic vascular patterns were significantly associated with the incidence of DVT. Patients older than 65 years had an odd ratio (OR) of 3.23, and younger patients had an OR of 1[176]. February 19, 2022

Volume 12 Issue 2 Early identification and treatment of catatonia and its underlying cause are crucial to rapidly improve stupor and prevent all these complications [5, 6, 144] . Specific preventative measures include frequent vital sign checks, anticoagulation, postural changes, intravenous fluids, nasogastric feeding, and urinary catheterization [165] . Additionally, the progression to malignant catatonia with autonomic instability and hyperthermia is a life-threatening condition that should be watched.

Catatonia in older people is an underrecognized entity and is consequently undertreated, as evidenced by the scarce literature found after a systematic search. The majority of articles are case reports or case series, with few prospective studies. However, a very interesting fact is evident: Most case descriptions show similar medical and psychiatry histories, clinical manifestations, etiologies, comorbidities and responses to treatment; clinical correlates that are very similar to those cases reported by prospective studies.

Catatonia in this population is highly prevalent, and the prevalence increases when the clinical setting studied is more specific (general hospital: 5.5% There is some evidence that supports the possibility that somatic and cognitive impairment have a significant role in the development of catatonia [16] . This could be related to the highest prevalence of dementia and medical disorders, such as cardiovascular risk factors (hypertension, type 2 diabetes mellitus, and dyslipidemia), in this population [178] , which were present in most case reports described in the United Kingdom psychogeriatric ward (Table 1 ) and in all patients of the psychiatry liaison consultation studies [8, 14] (the other 2 prospective studies did not specify these data). It has been considered whether dementia is a specific risk factor for developing catatonia. Takács et al [15] , in a study in a general psychiatry ward, concluded that it was not a risk factor, as the prevalence of catatonia was not very different in their patients with dementia (4.7%) compared to the total study sample (6.1%). However, in studies on psychogeriatric wards, the prevalence was higher in patients with dementia (35.3%[16] and 42.8%[11]) than in the total number of patients [20.8%[16] and 24.3% (Table 1) ]. This nonconcordance could be caused by differences in the clinical settings and leaves open the role of dementia as a risk factor for catatonia.

The clinical presentation of catatonia is quite similar to that of adults under 65 years of age. In general, the most frequent signs are the same (immobility, staring, mutism, negativism, withdrawal, rigidity and posturing) [5, 12, 38] . Unlike what happens in patients under 65 years of age, excitement (41.8%), verbigeration (37.9%), perseveration (33%) and autonomic abnormalities (27.8%) seem to also be very frequent. In older people, the high prevalence of dementia and cardiovascular risk factors could also explain this different profile. In all catatonia prospective studies, the assessment was undertaken in a systematic way using the BFCRS; notably, the low frequency of the catatonic signs considered DSM-5 diagnostic criteria [ecophenomena (17,7%), grimacing (15,3%), waxy flexibility (7,6%) and mannerism (5,1%)] and the high frequency of other catatonic signs included in the BFCRS and not the DSM-5 criteria [staring (62%), withdrawal (45,6%) rigidity (45,6%) and autonomic abnormalities (27,8%)] (Table 3) . These results could suggest the need to review the very strict current diagnostic criteria and to take into account what was reported by Stuivenga et al [12] , that giving a dimensional approach to catatonic signs could help improve diagnostic sensitivity. In older people, it may be better to use, in an initial assessment, the Bush Francis Catatonia Screening Instrument, which includes the above catatonic signs, to identify more patients susceptible to receiving potentially very effective treatment.

Catatonia and delirium co-occur relatively frequently in older people. Management could be a challenge for clinicians; however, if we follow a therapeutic and care algorithm, the chances of better February 19, 2022

Volume 12 Issue 2 results are greater [32] . A systematic review on the issue recommended identifying and treating the etiology of both conditions, initially trying a challenge test with lorazepam; avoiding the use of highpotency neuroleptics; taking the necessary measures to prevent and treat complications; and if there is no response with lorazepam, considering the use of amantadine, memantine or topiramate. ECT is indicated in refractory or life-threatening cases [32] . The probability that catatonia in acute medical settings has a medical etiology or is related to drug use/withdrawal is greater than 50%. The prevalence of catatonia was strongly associated with age in the setting of critical illness [179] . This probability increases in critically ill elderly patients by up to 80%-100%[33]. These high rates of catatonia in clinical settings should lead us to consider that the etiology of catatonia is medical until proven otherwise, especially in older adults [33] . It has been frequently reported that the possible organic etiology of patients with catatonia tends to be overlooked, even more so if they have a psychiatric history because of a belief that the psychiatric disorder is the cause of catatonia [143, 180] .

In almost all dementia cases traced, these disorders were not the cause of catatonia; rather, they emerged as a consequence of the acute onset of psychopathology, GMCs, and/or due to the use of drugs, mainly neuroleptics. This occurred in 29 of 31 (93.5%) patients with dementia reported in observational prospective studies[8,11,14-16]. This does not appear to occur in FTD patients. Catatonia and FTD share a common pathophysiology, frontal lobe dysfunction, and similar symptoms (mutism, stupor, stereotypy, mannerisms, perseveration, negativism, echophenomena, and others [44] , which are a central part of their diagnostic criteria [2, 181] . This could cause catatonia to be even more underdiagnosed and therefore not adequately treated in this specific type of dementia. In FTD, catatonia should be suspected when the patient has a sudden and sustained increase in previous psychomotor symptoms or when the appearance of new catatonic symptoms is observed. In the rest of the reports of catatonia secondary to neurological disorders, GMCs and the use of drugs, something similar takes place. Catatonia occurs frequently when GMCs cause psychotic or depressive symptoms or when the latter appear as drug adverse effects and/or in patients with a psychiatric history of disorders of both spectra. In future studies, the systematic evaluation of the presence or absence of depressive or psychotic psychopathology in these patients will reveal their roles in the development of catatonia.

In general, in this population, antipsychotics can also increase the risk of NMS and can contribute to the development or worsening of catatonic symptoms [182, 183] . Moreover, the NMS risk of poor outcome and mortality is associated with older age [184] . Some authors have recommended antipsychotic discontinuation during the acute phase of catatonia and to reinitiate treatment once catatonia is in remission [5, 185] . Due to the risks concerning the safety of antipsychotics, their use in acute catatonia is generally not recommended in this population [185] . Caution should be the rule on prescribing, and the risk assessment should be individualized to each patient [6] . Catatonia can also appear after withdrawal from different types of drugs, mainly BZDs. The predominant subtype was stuporous catatonia with sporadic reports of catatonic excitement. Given that BZD withdrawal is more frequently associated with motor hyperactivity, excited catatonia may not be reported as such [128] . A significant number of these reports described a series of concurrent psychiatric and GMCs that could have played a role in the development of catatonia, mainly depression[128], dementia[57], pneumonia, and infectious exacerbation of chronic obstructive pulmonary disease[128]. Rosebush and Mazurek [186] suggest the possibility that older individuals may be more vulnerable to developing catatonia upon BZD withdrawal, particularly if the drug is rapidly tapered or abruptly discontinued in patients who have taken them for a long time.

In relation to catatonia secondary to psychiatric conditions, this syndrome is more frequently associated with mood disorders than with SSD, as occurs in patients between 18 and 65 years of age. In this population, mood disorders were associated with a 2.7-fold higher risk of developing catatonia compared to psychotic conditions [16] . Again, in patients with affective disorders, age could be a risk factor for developing catatonia. A naturalistic cohort study in BD patients showed that it could present more frequently in older people with catatonic features compared with younger people [187] . As in affective conditions, most of the reports of catatonia in SSD patients have acute psychotic and/or depressive psychopathology and various organic disorders. Although catatonia has been described in practically all the mental conditions of our classification systems, in older adults, cases published outside of affective and SSD disorders are anecdotal and probably due to lack of recognition.

General treatment recommendations on catatonia are derived from case reports or observational studies due to the lack of randomized controlled trials [188] . Despite a possible publication bias, usual treatments, such as BZDs and ECT, show excellent response rates and are considered effective in older adults [5, 6, 143, 144] . Lorazepam is the most extensively used BZD, but other options (Table 5) were tested with good responses. ECT is considered the most successful treatment for catatonia. It is also a safe and effective option for treating catatonia in older patients, regardless of the etiology[5,6]. Some studies have suggested that ECT may be more effective in older patients than in other age groups [139] . It remains controversial whether ECT should be considered a first-line treatment in older patients when catatonia symptoms appear in the context of a MDD [150] . Faster and higher remission rates have been described with ECT in comparison with antidepressant medications. Therefore, it seems reasonable to consider ECT as a priority option if catatonia is present and the underlying condition is also responsive to ECT [150] . There are interesting descriptions of the response to catatonia treatment with other drugs; February 19, 2022

Volume 12 Issue 2 however, we can consider these options as a third-line treatment because of the limited literature available on the matter (Table 5) . Our review has important limitations, the main one being that all the conclusions are based on the results of mostly case reports and few prospective studies. Publication bias may be present, and the heterogeneity of the prospective studies does not allow for qualitative analysis. The hypotheses presented here will have to be confirmed in prospective studies designed specifically for that purpose. However, the clinical correlates of all these cases significantly coincide with the results of prospective studies, regardless of the year or place of publication or etiology of catatonia. The most important strength is the summarizing of all the bibliographies on catatonia in older adults published since inception in the main medical databases until December 2021, using articles obtained through a systematic search following the PRISMA recommendations.

Catatonia in older people is highly prevalent and is associated with affective disorders, GMCs, and SSDs in that order of frequency, although its etiology is frequently multifactorial. GMCs, mainly dementia and other neurologic disorders, have a significant role in the etiology, and this is sometimes overlooked. Older patients, compared to younger patients, have a higher risk of developing catatonia in BD, in psychiatric liaison services, and they may be more vulnerable to developing catatonia with BZD withdrawal. Age, together with other risk factors, was significantly associated with the incidence of DVT, NMS poor outcome, other complications and mortality. The response to symptomatic treatment with BZDs and ECT is very good and safe, and other effective options are also available. The simultaneous treatment of the etiology of catatonia is also fundamental. Specifically, designed prospective studies are needed to more accurately identify the clinical correlates of catatonia in older people.

Catatonia in older people is an underrecognized and undertreated systemic medical syndrome despite having specific treatment that has shown great effectiveness. These patients are at increased susceptibility of developing potentially life-threatening complications.

Systematic reviews on this topic have not been conducted. Similar previous reviews were not systematic, and since their publication, the number of papers in this regard has practically doubled. We considered that an update was necessary.

This review aimed to synthesize all the published literature related to catatonia in older patients. This summary will provide up-to-date knowledge about this condition.

A comprehensive systematic review was conducted according to PRISMA recom-mendations. An extensive search strategy was developed, and the MEDLINE, EMBASE, and PsycINFO databases were searched. Screening was completed in duplicate. Papers that investigated issues related to catatonia and/or catatonic symptoms in older people with an English abstract available were included. Additionally, we provided all the clinical correlates of our series of catatonia in a psychogeriatric ward.

In total, 173 articles were considered in this systematic review. Most of them were case reports and case series (143) , and only 11 were prospective cohort studies. Catatonia in older people is highly prevalent, and in most cases, its etiology is multifactorial. Neurological disorders could play a very important role in catatonia development; in part, cardiovascular risk factors could explain this association. BZDs and ECT are very effective and well tolerated treatments.

This systematic review provides a comprehensive summary of catatonia in older people. These patients have a higher risk of developing catatonia than younger patients with BD in the general hospital and secondary to BZD withdrawal. Age is related, within other risk factors, to poor NMS prognosis and the development of complications.

Catatonia as a rare manifestation of gabapentin withdrawal

Brief psychotic disorder mimicking the symptoms of cerebrovascular attack evoked by symptoms that symbolized death in a patient with terminal stage stomach cancer: case report and review of the literature

Severe depression masquerading as Creutzfeldt-Jakob disease

Effectiveness of electroconvulsive therapy for Cotard's syndrome accompanied by catatonia: A case report

Cotard's syndrome with catatonia: a case presentation and discussion

One-year outcome after response to ECT in middle-aged and elderly patients with intractable catatonic schizophrenia

Lorazepam for psychogenic catatonia

Benzodiazepines and catatonia: a case report

Catatonia as an unusual presentation of posttraumatic stress disorder

Catatonia in the elderly

The Lorazepam and Diazepam Protocol for Catatonia Due to General Medical Condition and Substance in Liaison Psychiatry

Benzodiazepine Treatment of Catatonia in the Elderly

Midazolam and the treatment of catatonia in major depression in an older adult

Use of Subcutaneous Midazolam During an Episode of Catatonia

Catatonia: Not just another "mental status change

Safety of benzodiazepines in the geriatric population

Electroconvulsive Therapy in Geriatric Psychiatry: A Selective Review

Refractory catatonia in old age: a case report

Successful use of right unilateral ECT for catatonia: a case series

Ultrabrief Right Unilateral Ect and Catatonia: a Case Series and Literature Review

Resolution of catatonia by successful seizure induction via electroconvulsive therapy with electrodes applied bilaterally to the parietotemporal region

Manganese neurotoxicity presenting with depression, psychosis and catatonia

Successful electroconvulsive therapy in a 95-year-old man with a cardiac pacemaker--a case report

Electroconvulsive therapy and anticoagulation after pulmonary embolism: A case report

Electroconvulsive therapy for treatment of major depression in a 100-year-old patient with severe aortic stenosis: a 5-year follow-up report

Electroconvulsive Therapy for Catatonia With Deep Venous Thrombosis: A Case Series

The effect of electroconvulsive therapy on autobiographical memory: a systematic review

Ictal catatonia as a manifestation of nonconvulsive status epilepticus

Successful use of olanzapine for catatonia following delirium

Alternative treatment strategies for catatonia: A systematic review

Neuroleptic malignant syndrome: a case responding to electroconvulsive therapy plus bupropion

Guidelines for preventing common medical complications of catatonia: case report and literature review

Topiramate effect in catatonia: a case series

Catatonia: an open prospective series with carbamazepine

Refractory depression with catatonic features was remitted with administration of intravenous dopamine and consequent bupropion as maintenance treatment

van den Hoven DJ, aan de Stegge BM, Ayodeji ID. Remission of catatonia after intravenous propofol infusion for unrelated reasons

A case report of cholinergic rebound syndrome following abrupt low-dose clozapine discontinuation in a patient with type I bipolar affective disorder

Treatment of catatonia with intravenous biperidene

Stuporous catatonia in an elderly bipolar patient: response to olanzapine

Catatonia associated with late-life psychosis successfully treated with lithium: a case report

Transcranial Direct Current Stimulation for Treating Depression in a Patient With Right Hemispheric Dominance: A Case Study

Incidence of deep vein thrombosis in catatonic patients: A chart review

Catatonia on the consultation-liaison service: a replication study

Comorbidity in older adults: nosology of impairment, diseases, and conditions

Advanced Age Is Associated With Catatonia in Critical Illness: Results From the Delirium and Catatonia Prospective Cohort Investigation

Suspected Delirium Predicts the Thoroughness of Catatonia Evaluation

Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria

Catatonia: diagnosis, classification, and treatment

The use of atypical antipsychotics in the treatment of catatonia

A systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic malignant syndrome

Risk of death in elderly users of conventional vs. atypical antipsychotic medications

Catatonia after benzodiazepine withdrawal

Bipolar disorder in the elderly: a cohort study comparing older and younger patients

Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses